What the label lists and what reports show
Almotriptan side effects
Almotriptan's FDA label: “The most common adverse reactions during treatment with almotriptan tabletswere nausea, somnolence, headache, paresthesia, and dry mouth.” FAERS holds 1,008 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is hyperhidrosis (448 reports).
- Generic listed
Check it at the source: the almotriptan FDA label on DailyMed (effective December 31, 2025, Ajanta Pharma USA Inc.); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsThe most common adverse reactions during treatment with almotriptan tabletswere nausea, somnolence, headache, paresthesia, and dry mouth.
Table 2: Adverse Reactions Reported by ≥1% of Adolescent Patients Treated with Almotriptan Tablets in 1 Placebo-Controlled, Double-Blind Clinical Trial
| System/Organ Class Adverse Reaction | Almotriptan Tablets 6.25 mg (n=180) % | Almotriptan Tablets 12.5 mg (n=182) % | Placebo (n=172) % |
|---|---|---|---|
| Dizziness | 4 | 3 | 2 |
| Somnolence | <1 | 5 | 2 |
| Headache | 1 | 2 | 1 |
| Paresthesia | <1 | 1 | <1 |
| Nausea | 1 | 3 | 0 |
| Vomiting | 2 | 0 | <1 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedSerious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD. Reactions reported in association with triptans have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation [see Contraindications ( 4.1 ) and Warnings and Precautions ( 5.1 )]. The following adverse reactions are discussed in more detail in other sections of the labeling: Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events [see Warnings and Precautions ( 5.1 )] Sensations of Pain, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw [see Warnings and Precautions ( 5.2 )] Cerebrovascular Events and Fatalities [see Warnings and Precautions ( 5.3 )] Other Vasospasm-Related Events, Including Peripheral Vascular Ischemia and Colonic Ischemia [see Warnings and Precautions ( 5.4 )] Serotonin Syndrome [see Warnings and Precautions ( 5.5 )] Increases in Blood Pressure [see Warnings and Precautions ( 5.7 )] Adverse events were assessed in controlled clinical trials that included 1840 adult patients who received one or two doses of almotriptan tablets and 386 adult patients who received placebo. …
Source: FDA drug label, Ajanta Pharma USA Inc., effective December 31, 2025 (SPL set 6fa380c4-c885-4743-85bf-88819ae68645), via openFDA; the full label on DailyMed
What do FAERS reports show?
1,008 reports list almotriptan among the medicines taken, each a report of something that happened, not proof the medicine caused it; 48 are coded as a death and 210 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 16 reactions below, 12 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Almotriptan: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions